Phencyclidine (PCP)-Induced Deficits in Novel Object Recognition

Nichole M Neugebauer*, Lakshmi Rajagopal, Mei Huang, Herbert Y Meltzer

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations

Abstract

Subchronic administration of phencyclidine (PCP), an NMDAR antagonist, produces a variety of cognitive impairments in rodents. Of these, novel object recognition, a type of declarative memory, has been widely used to study the pathophysiology resulting from PCP treatment. There is evidence for the ability of atypical antipsychotic drugs (AAPDs), through direct and indirect effects on serotonin (5-HT)1A, 5-HT2A, 5-HT7, and DA D2 receptors to prevent acutely and to enduringly reverse the effects of subchronic PCP on novel object recognition. The neuropathology of subchronic PCP and a possible role of neurogenesis in the actions of the atypical antipsychotic drugs to improve cognition in schizophrenia are discussed.

Original languageEnglish (US)
Title of host publicationStimulants, Club and Dissociative Drugs, Hallucinogens, Steroids, Inhalants and International Aspects
PublisherElsevier Inc.
Pages723-732
Number of pages10
Volume2
ISBN (Electronic)9780128003756
ISBN (Print)9780128002124
DOIs
StatePublished - Apr 15 2016

Keywords

  • Atypical antipsychotics
  • Cognitive impairment
  • NMDA antagonist
  • Object recognition
  • Phencyclidine

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Phencyclidine (PCP)-Induced Deficits in Novel Object Recognition'. Together they form a unique fingerprint.

  • Cite this

    Neugebauer, N. M., Rajagopal, L., Huang, M., & Meltzer, H. Y. (2016). Phencyclidine (PCP)-Induced Deficits in Novel Object Recognition. In Stimulants, Club and Dissociative Drugs, Hallucinogens, Steroids, Inhalants and International Aspects (Vol. 2, pp. 723-732). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-800212-4.00067-4